Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT. (clinicaltrials.gov) - May 7, 2026 - P4 | N=120 | Recruiting | Sponsor: WeiShi
New P4 trial • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|